AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23964144 — intervention group
Group type: COMPARATOR
Intervention: NaP preparations (comparing all NaP preparations to PEG preparations)
Number of subjects: 349
Study 23964144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl (in combination with NaP or PEG)
Number of subjects: 349
Study 23964144 — intervention group
Group type: COMPARATOR
Intervention: Whole dose NaP preparation (compared to half-dose PEG plus bisacodyl)
Number of subjects: 349
Study 20466530 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4818 300 mug twice daily
Number of subjects: 65
Study 18212717 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music for 15 minutes
Number of subjects: 30
Study 18212717 — intervention group
Group type: COMPARATOR
Intervention: No music (15-minute rest)
Number of subjects: 30
Study 16489477 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion for 1 hour, twice a day, following total knee replacement surgery.
Number of subjects: 85
Study 16489477 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation protocol without continuous passive motion (Control group).
Number of subjects: 85
Study 12860346 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against HPV16 E7 in SB adjuvant ASO2B
Number of subjects: 5
Study 12860346 — intervention group
Group type: COMPARATOR
Intervention: Non-injected patients
Number of subjects: 5
Study 10881949 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition and conventional intravenous fluids (n = 11)
Number of subjects: 29
Study 10881949 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous fluids only (n = 18)
Number of subjects: 29
Study 10881949 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 additional patients with major abdominal operations)
Number of subjects: 29
Study 9433635 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8494127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg, twice daily
Number of subjects: 28
Study 8494127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg, twice daily
Number of subjects: 28
Study 8494127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2963205 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous oestrogen therapy for 2 years, opposed by oral micronized progesterone (200 mg) during the second year
Number of subjects: 110
Study 2963205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17 beta‐oestradiol valerate together with cyproterone acetate (CPA)
Number of subjects: 110
Study 30431725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) switched on
Number of subjects: 44
Study 30431725 — intervention group
Group type: COMPARATOR
Intervention: Low-Level Laser Therapy (LLLT) switched off
Number of subjects: 44
Study 26931110 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled oral analgesia
Number of subjects: 77
Study 26931110 — intervention group
Group type: COMPARATOR
Intervention: Parenteral analgesia
Number of subjects: 77
Study 26931110 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study 24967725 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifting training (n=9)
Number of subjects: 17
Study 24967725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (language and respiratory exercises, n=8)
Number of subjects: 17
Study 22779286 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% acidulated phosphate fluoride (APF) gel
Number of subjects: 12
Study 20397811 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV (Non-Invasive Positive Pressure Ventilation) restarted after 1 week of withdrawal
Number of subjects: 10
Study 20397811 — intervention group
Group type: COMPARATOR
Intervention: Continued withdrawal from NIPPV for up to 6 months
Number of subjects: 10
Study 18547537 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal implants (neural retinal progenitor cell layers with retinal pigment epithelium)
Number of subjects: 10
Study 15821644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (20 ppm)
Number of subjects: 41
Study 15821644 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng x kg ‐1 x min ‐1)
Number of subjects: 41
Study 15821644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide plus iloprost
Number of subjects: 41
Study 15821644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41
Study 15821644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide and nitric oxide plus iloprost
Number of subjects: 41
Study 12399676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 192
Study 12399676 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (control group)
Number of subjects: 192
Study 9678143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin gel with hygroscopic cervical dilators
Number of subjects: 40
Study 9678143 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin gel alone
Number of subjects: 40
Study 8008103 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient point-of-view (PPOV1) delivery of regularly ordered medication by a pharmacy technician to the nurse server once a day
Number of subjects: 37
Study 8008103 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient point-of-view (PPOV2) delivery of all medications (including stats and i.v.s) to the nurse server hourly between 0700 and 2300 hours
Number of subjects: 37
Study 8008103 — intervention group
Group type: COMPARATOR
Intervention: Traditional medication cart
Number of subjects: 37
Study 2686797 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone
Number of subjects: 51
Study 2686797 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 51
Study 1092283 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 714
Study 1092283 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 714
Study 1092283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study 1092283 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Chlorpromazine, Imipramine, Placebo)
Number of subjects: 714
Study 6160280 — intervention group
Group type: COMPARATOR
Intervention: Trimecaine (2 mg/min IV after 80 mg jet-injection)
Number of subjects: 45
Study 6160280 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (same schedule as trimecaine)
Number of subjects: 45
Study 6160280 — intervention group
Group type: COMPARATOR
Intervention: Control (no antiarrhythmic agents)
Number of subjects: 45
Study 31763300 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mitomycin (0.4 mg/ml) applied for 5 min
Number of subjects: 80
Study 31763300 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control) applied for 5 min
Number of subjects: 80
Study 28645428 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 201
Study 28645428 — intervention group
Group type: COMPARATOR
Intervention: Primary cytoreductive surgery
Number of subjects: 201
Study 25735310 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-ABT (ankle balance taping with kinesiology tape)
Number of subjects: 9
Study 25735310 — intervention group
Group type: COMPARATOR
Intervention: No-ABT (control)
Number of subjects: 9
Study 25735310 — intervention group
Group type: COMPARATOR
Intervention: Placebo-ABT (control)
Number of subjects: 9
Study 23136121 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavan-3-ol-enriched dark chocolate
Number of subjects: 42
Study 23136121 — intervention group
Group type: EXPERIMENTAL
Intervention: White chocolate
Number of subjects: 42
Study 21160192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release dinoprostone vaginal pessary followed 6 h later by high-dose oxytocin infusion
Number of subjects: 500
Study 21160192 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release dinoprostone vaginal pessary with concurrent high-dose oxytocin infusion
Number of subjects: 500
Study 21160192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release dinoprostone pessary followed 6 h later by high-dose oxytocin
Number of subjects: 500
Study 19346225 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior CABG patients
Number of subjects: 1026
Study 19346225 — intervention group
Group type: COMPARATOR
Intervention: No prior CABG patients
Number of subjects: 1026
Study 17724829 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with prostamol Uno and tamsulosin
Number of subjects: 58
Study 17724829 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with prostamol Uno
Number of subjects: 58
Study 14747429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (day 1: 400 mg; days 2-4: 200 mg) + Lumiracoxib (400 mg on day 4)
Number of subjects: 13
Study 14747429 — intervention group
Group type: COMPARATOR
Intervention: Lumiracoxib (400 mg on day 4)
Number of subjects: 13
Study 11391683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowman-Birk inhibitor concentrate (BBIC)
Number of subjects: 19
Study 11391683 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19
Study 9521027 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy and treatment with HSE
Number of subjects: 293
Study 9521027 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy alone
Number of subjects: 293
Study 7994786 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 150
Study 7994786 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 150
Study 2683685 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instruction treatment using a modified version of the LOGO computer language (REFLECT) and videotape feedback
Number of subjects: 16
Study 2683685 — intervention group
Group type: COMPARATOR
Intervention: LOGO problem-solving without self-instruction (Control)
Number of subjects: 16
Study 1092765 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified type 1 M protein vaccine
Number of subjects: 44
Study 1092765 — intervention group
Group type: COMPARATOR
Intervention: Buffer placebo
Number of subjects: 44
Study 31634231 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinflammatory subphenotype (39/104 ARDS patients)
Number of subjects: 212
Study 31634231 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinflammatory subphenotype (30/108 ARFA patients)
Number of subjects: 212
Study 31634231 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent elevation of biomarkers of innate immunity
Number of subjects: 212
Study 31634231 — intervention group
Group type: COMPARATOR
Intervention: Hypoinflammatory subphenotype
Number of subjects: 212
Study 28578889 — intervention group
Group type: EXPERIMENTAL
Intervention: Telescopic-coated dental needle
Number of subjects: 60
Study 28578889 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental needle
Number of subjects: 60
Study 26104503 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention
Number of subjects: 171
Study 26104503 — intervention group
Group type: COMPARATOR
Intervention: Comparison health and wellness intervention
Number of subjects: 171
Study 26104503 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (decreased sports/exercise)
Number of subjects: 171
Study 26104503 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (maintained/increased sports/exercise)
Number of subjects: 171
Study 24127444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetra-arsenic tetra-sulfide (RIF) 60 mg/kg
Number of subjects: 242
Study 24127444 — intervention group
Group type: COMPARATOR
Intervention: Intravenous arsenic trioxide (ATO) 0.16 mg/kg
Number of subjects: 242
Study 24127444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetra-arsenic tetra-sulfide (RIF) plus ATRA
Number of subjects: 242
Study 24127444 — intervention group
Group type: COMPARATOR
Intervention: Intravenous arsenic trioxide (ATO) plus ATRA
Number of subjects: 242
Study 21273347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 471
Study 21273347 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with bevacizumab
Number of subjects: 471
Study 21273347 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin users
Number of subjects: 471
Study 21273347 — intervention group
Group type: COMPARATOR
Intervention: Control group (Capecitabine monotherapy)
Number of subjects: 471
Study 19584184 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine administered in a fasting state
Number of subjects: 65
Study 19584184 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine taken with breakfast
Number of subjects: 65
Study 19584184 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine taken at bedtime
Number of subjects: 65
Study 17215531 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of nevirapine
Number of subjects: 218
Study 17215531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 15217581 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy IMRT (group A)
Number of subjects: 23
Study 15217581 — intervention group
Group type: EXPERIMENTAL
Intervention: 66-70 Gy IMRT (group B)
Number of subjects: 23
Study 15217581 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute skin toxicities
Number of subjects: 23
Study 15217581 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute mucositis
Number of subjects: 23
Study 15217581 — intervention group
Group type: EXPERIMENTAL
Intervention: Late xerostomia at 3 months
Number of subjects: 23
Study 12201825 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological dose (0.0017 mg/kg/day)
Number of subjects: 13
Study 12201825 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological dose (0.0033 mg/kg/day)
Number of subjects: 13
Study 12201825 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiological dose (0.010 mg/kg/day)
Number of subjects: 13
Study 12201825 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiological dose (0.025 mg/kg/day)
Number of subjects: 13
Study 12201825 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall increase in GH dose
Number of subjects: 13
Study 9717787 — intervention group
Group type: COMPARATOR
Intervention: Heater probe
Number of subjects: 41
Study 9717787 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation
Number of subjects: 41
Study 7863248 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg nizatidine nocte (n = 86)
Number of subjects: 269
Study 7863248 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 150 mg/d nizatidine (n = 93)
Number of subjects: 269
Study 7863248 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 300 mg/d nizatidine (n = 90)
Number of subjects: 269
Study 7863248 — intervention group
Group type: COMPARATOR
Intervention: nizatidine 150 mg nocte (116 patients)
Number of subjects: 269
Study 7863248 — intervention group
Group type: COMPARATOR
Intervention: 2 x 150 mg nizatidine daily (121 patients)
Number of subjects: 269
Study 2683542 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin, 0.8 mg/kg i.v. preoperatively followed by 100 mg rectally 8-hourly for 3 days
Number of subjects: 20
Study 2683542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 782497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (400 mug daily)
Number of subjects: 158
Study 782497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled betamethasone valerate (800 mug daily)
Number of subjects: 158
Study 782497 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 158
Study 782497 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (all types)
Number of subjects: 158
Study 782497 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of beclomethasone dipropionate
Number of subjects: 158
Study 782497 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal response to tetracosactrin
Number of subjects: 158
Study 782497 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal function suppression
Number of subjects: 158
Study 31469259 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate strengthened lithium aluminosilicate glass-ceramic (LAS)
Number of subjects: 35
Study 31469259 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional lithium-disilicate glass-ceramic (LDS)
Number of subjects: 35
Study 31469259 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation polymer-based CAD/CAM resin composite (CS)
Number of subjects: 35
Study 28088597 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) applied to the incision from postoperative days 1 through 4
Number of subjects: 265
Study 28088597 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressing (SSD) applied to the incision from postoperative days 1 through 4
Number of subjects: 265
Study 28088597 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 265
Study 28088597 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical dressing (SSD)
Number of subjects: 265
Study 25465944 — intervention group
Group type: COMPARATOR
Intervention: Finasteride 5 mg alone
Number of subjects: 15
Study 25465944 — intervention group
Group type: COMPARATOR
Intervention: Finasteride 5 mg with Tamsulosin 0.2 mg
Number of subjects: 15
Study 25465944 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg alone
Number of subjects: 15
Study 25465944 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg with Finasteride 5 mg
Number of subjects: 15
Study 23368701 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid and carboxymethylcellulose (HA/CMC) instillation after TURP
Number of subjects: 180
Study 23368701 — intervention group
Group type: COMPARATOR
Intervention: Lubricant instillation after TURP (Control)
Number of subjects: 180
Study 20421867 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (VACV) 1000 mg twice daily
Number of subjects: 53
Study 20421867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 19060462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream plus colchicine tablets (1-2 g/day)
Number of subjects: 76
Study 19060462 — intervention group
Group type: COMPARATOR
Intervention: Colchicine tablets (1-2 g/day)
Number of subjects: 76
Study 17084566 — intervention group
Group type: COMPARATOR
Intervention: 25 g of soy protein (SP)
Number of subjects: 46
Study 17084566 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of soy protein plus resistance exercise (SPE)
Number of subjects: 46
Study 17084566 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus resistance exercise (PLE)
Number of subjects: 46
Study 17084566 — intervention group
Group type: COMPARATOR
Intervention: 25 g of maltodextrine (placebo) (PL)
Number of subjects: 46
Study 14679365 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Wine (RW) 500 ml/day (12% ethanol)
Number of subjects: 24
Study 14679365 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% ETOH dilution 500 ml/day
Number of subjects: 24
Study 14679365 — intervention group
Group type: COMPARATOR
Intervention: Dealcoholized Red Wine (DRW) 500 ml/day
Number of subjects: 24
Study 14679365 — intervention group
Group type: COMPARATOR
Intervention: Red Grape Juice (RGJ) 500 ml/day
Number of subjects: 24
Study 11179106 — intervention group
Group type: EXPERIMENTAL
Intervention: NO2 (10-μg/m3 increment)
Number of subjects: 3912
Study 11179106 — intervention group
Group type: EXPERIMENTAL
Intervention: TSP (10-μg/m3 increment)
Number of subjects: 3912
Study 11179106 — intervention group
Group type: EXPERIMENTAL
Intervention: O3 (10-μg/m3 increment)
Number of subjects: 3912
Study 9215818 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide 100 mg/m2 orally on days 1 to 14, methotrexate 40 mg/m2 intravenously on days 1 and 8, fluorouracil 600 mg/m2 intravenously on days 1 and 8)
Number of subjects: 232
Study 9215818 — intervention group
Group type: COMPARATOR
Intervention: LMF (chlorambucil 5 mg/m2 orally on days 1 to 14 with some I.V. cytostatic drugs)
Number of subjects: 232
Study 9215818 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 232
Study 9215818 — intervention group
Group type: COMPARATOR
Intervention: LMF
Number of subjects: 232
Study 8299603 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 10
Study 8299603 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia
Number of subjects: 10
Study 3106607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 324
Study 3106607 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 324
Study 29358444 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme (HBEP) for 12 weeks, including step targets and resistance exercises.
Number of subjects: 20
Study 26826622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stents (SES)
Number of subjects: 1724
Study 26826622 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel eluting stents (PES)
Number of subjects: 1724
Study 26826622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stents (SES) in insulin-treated patients
Number of subjects: 1724
Study 26826622 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel eluting stents (PES) in insulin-treated patients
Number of subjects: 1724
Study 26826622 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic follow-up presence
Number of subjects: 1724
Study 26826622 — intervention group
Group type: COMPARATOR
Intervention: Angiographic follow-up absence
Number of subjects: 1724
Study 23451852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied twice daily for 2 months
Number of subjects: 30
Study 23451852 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment applied twice daily for 2 months
Number of subjects: 30
Study 23290165 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (first tablet taken within 24 hours post-operation, administered daily for 14 days)
Number of subjects: 100
Study 23290165 — intervention group
Group type: COMPARATOR
Intervention: Control (no anticoagulant postoperatively)
Number of subjects: 100
Study 23290165 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 100